Drug mix ‘extends life of breast cancer patients’
the Guardian -

Trial finds combination therapy can benefit those at final stage of disease

Combining the newly developed drug palbociclib with hormone therapy substantially extends the lives of women with advanced breast cancer, scientists announced yesterday.

Women with metastatic cancer who were given the combination therapy lived seven months longer than those who were treated with hormones alone. And in women who had previously responded to hormone therapy, these extended survival times reached an average...

In related news